Professor Easton said that Table 1 of the 981 Patent specification indicated that small structural modifications to the compounds encompassed in claim 1 could substantially increase HMG-CoA reductase inhibitory activity. Dr Scallen in his affidavit evidence said that he read the CSI Table as asserting that the R-trans enantiomer was approximately ten times as active as the racemate, and that the reason for including it was to lay some foundation for the claims of unexpected and surprising inhibition of cholesterol synthesis. A surprising level of difference in activity. This is commonly described as 'SAR' work. 118 and 124.